ACS Nano

1. ZHENG R, Xiao Y, Yang J, Mao Z, et al
   Extracellular Vesicle-Packaged MIR4435-2HG Facilitates Cigarette Smoke-Induced Bladder Cancer Progression through Enolase 1-Dependent Glycolytic Reprogramming.
   ACS Nano. 2025 Dec 5. doi: 10.1021/acsnano.4c15108.
   

   >> Share

   
   

   
   Adv Radiat Oncol

2. HAYWORTH SB, Hotsinpiller WS, Pogue J, Tyler M, et al
   Early Experience Comparing Reduced Planning Target Volume Margins Using Cone Beam Computed Tomography Scan Guided Online Adaptive Radiation Therapy to Nonadaptive, Traditional Margin Plans for Muscle-Invasive Bladder Cancer.
   Adv Radiat Oncol. 2025;11:101934.
   

   >> Share

   
   

   
   Adv Sci (Weinh)

3. JIANG Y, Zhang Q, Zhang Y, Yu X, et al
   NIR-Activatable Domino Cascade Catalysis Nanozyme Reactor for Multi-Mechanism Synergistic Immunotherapy in Bladder Cancer.
   Adv Sci (Weinh). 2025 Dec 12:e13913. doi: 10.1002/advs.202513913.
   

   >> Share

   
   

   
   Ann Med Surg (Lond)

4. TAJ J, Ikkurthy N, Ekouo J
   Reappraising intravesical gemcitabine in BCG-unresponsive nonmuscle-invasive bladder cancer: lessons from contemporary re-analysis.
   Ann Med Surg (Lond). 2025;87:9189-9190.
   

   >> Share

   
   

   
   Arch Toxicol

5. ZHENG Y, Wu Y, Zhang J, Zhao C, et al
   Cigarette smoking combines with genetic variants to regulate FOXN3 and associate with bladder cancer risk.
   Arch Toxicol. 2025 Dec 8. doi: 10.1007/s00204-025-04244.
   

   >> Share

   
   

   
   Autophagy

6. DONG Y, Tian S, Peng X, Wang P, et al
   CCPG1-mediated reticulophagy promotes tumorigenesis and cisplatin resistance in bladder cancer.
   Autophagy. 2025 Dec 8. doi: 10.1080/15548627.2025.2601865.
   

   >> Share

   
   

   
   Biochem Pharmacol

7. JIANG WS, Yu FX, Liu YX, Song YS, et al
   Celastrol synergizes with MEK1 inhibitor nedometinib to overcome resistance in bladder cancer via dual suppression of CDK1/CDC5L and feedback-activated Akt/STAT3.
   Biochem Pharmacol. 2025 Dec 10:117629. doi: 10.1016/j.bcp.2025.117629.
   

   >> Share

   
   

   
   Biofactors

8. 
   Correction to "Knockdown of Integrin beta1 Inhibits Proliferation and Promotes Apoptosis in Bladder Cancer Cells".
   Biofactors. 2025;51:e70068.
   

   >> Share

   
   

   
   Biomater Res

9. DENG H, Huang J, Gao N, Liu Z, et al
   Erratum to "Nanotherapeutic System with Effective Microwave Sensitization and Pyroptosis Programming Enable Synergistic Microwave-Immunotherapy in Bladder Cancer".
   Biomater Res. 2025;29:0296.
   

   >> Share

   
   

   
   BJU Int

10. DI BELLO F, Gallioli A, Cannoletta D, Mancon S, et al
    Intravesical recurrence after therapeutic ureteroscopy for upper tract urothelial carcinoma: a meta-analysis.
    BJU Int. 2026;137:26-35.
    

    >> Share

    
    
11. MIEDERER M, Pretze M, Abbate E, Hartig A, et al
    Staging metastatic urothelial cancer with Nectin-4 imaging using Gallium-68-N188 PET/CT.
    BJU Int. 2026;137:166-172.
    

    >> Share

    
    

    
    BJUI Compass

12. TURAN S, Gezmis CT, Cilesiz NC, Uzut M, et al
    Haematuria cancer risk score as a predictor of muscle-invasive bladder cancer.
    BJUI Compass. 2025;6:e70125.
    

    >> Share

    
    

    
    Bladder Cancer

13. DADABHOY A, Doshi C, Zahir M, Sheybaee Moghaddam F, et al
    Impact of neighborhood deprivation on bladder cancer outcomes: A regional analysis.
    Bladder Cancer. 2025;11:23523735251406621.
    

    >> Share

    
    

    
    BMC Cancer

14. BLONDEAU A, Pitout A, Manuguerra A, Eschwege P, et al
    Sarcopenia measured by artificial intelligence as a predictor of overall survival in localized bladder cancer, a multicenter study.
    BMC Cancer. 2025 Dec 11. doi: 10.1186/s12885-025-15363.
    

    >> Share

    
    

    
    BMJ Case Rep

15. GIGOLA F, Mussini C, Hery G, Rigaud C, et al
    Primary bladder perivascular epithelioid cell tumour in an early adolescent.
    BMJ Case Rep. 2025;18:e262972.
    

    >> Share

    
    

    
    Cancer

16. ZHANG L, Liu Z, Ding Y, Sun J, et al
    Natural killer cell infiltration elicits gender-dependent dichotomous clinical outcomes in urothelial carcinoma.
    Cancer. 2025;131:e70196.
    

    >> Share

    
    

    
    Cancer Cell Int

17. JAZI NN, Alavimanesh S, Vafadar A, Choubani M, et al
    Theranostic potential of MXene-based platforms for dual MiRNA targeting in metastatic bladder cancer.
    Cancer Cell Int. 2025 Dec 11. doi: 10.1186/s12935-025-04084.
    

    >> Share

    
    

    
    Cancer Lett

18. ZHOU ZH, Wen JH, Zhang YZ, Yao K, et al
    Mitochondria-located circRCP regulates redox homeostasis via stabilizing LRPPRC/SLIRP complex to promote bladder urothelial carcinoma tumorigenesis.
    Cancer Lett. 2026;638:218157.
    

    >> Share

    
    

    
    Cancer Med

19. TAIHAO W, Chunkai D, Jingcheng L, Yichen Z, et al
    The Prognosis of Urothelial Carcinoma Between Kidney Transplantation Recipients and Normal Patients: A Propensity Score-Matched Study.
    Cancer Med. 2025;14:e71414.
    

    >> Share

    
    

    
    Cancers (Basel)

20. REGAZZO R, Ciccarese F, Paglialonga S, Reno E, et al
    High Prevalence of Smoking-Related Diseases in High-Grade and Muscle-Invasive Bladder Cancer: Opportunities for Lung Cancer Screening.
    Cancers (Basel). 2025;17:3741.
    

    >> Share

    
    

    
    Cell Biochem Biophys

21. YAN Y, Zhang H, Jia C, Xu H, et al
    Elevated NDRG1 Expression Drives Oxaliplatin Chemoresistance in Bladder Cancer Cells by Promoting Homologous Recombination Repair and Inhibiting G(2)/M Arrest.
    Cell Biochem Biophys. 2025 Dec 10. doi: 10.1007/s12013-025-01961.
    

    >> Share

    
    

    
    Cell Death Dis

22. TAO Y, Huang J, Hou J, Hu Z, et al
    Matrix stiffness maintains bladder cancer stemness via integrin-nuclear skeleton axis.
    Cell Death Dis. 2025;16:887.
    

    >> Share

    
    
23. TANG Y, Deng X, Wang Y, Zhou Q, et al
    NSUN2-mediated m5C modification of SOCS3 mRNA modulates macrophage polarization in bladder cancer.
    Cell Death Dis. 2025 Dec 7. doi: 10.1038/s41419-025-08306.
    

    >> Share

    
    

    
    Chem Commun (Camb)

24. ZHANG J, Ju X, Wang Z, Hao L, et al
    A multiple signal-amplified electrochemiluminescence biosensor for ultrasensitive detection of bladder cancer-associated circRNA in urine.
    Chem Commun (Camb). 2025 Dec 9. doi: 10.1039/d5cc05842.
    

    >> Share

    
    

    
    Clin Genitourin Cancer

25. SQUIRES P, Cook EE, Song Y, Wang CY, et al
    Treatment Patterns, Disease Recurrence, and Overall Survival in Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy: A Population-Level Claims-Based Analysis.
    Clin Genitourin Cancer. 2025;24:102466.
    

    >> Share

    
    

    
    Clin Nucl Med

26. RAEISI N, Saber Tanha A, Khooei A, Ataei N, et al
    Favorable 99m Tc-FAPI-46 Uptake in Primary Mucinous Adenocarcinoma of the Bladder.
    Clin Nucl Med. 2026;51:e55-e56.
    

    >> Share

    
    

    
    Clin Transl Med

27. JEONG MS, Mun JY, Yang GE, Baek SW, et al
    Lipocalin 2 as a potential liquid biopsy marker for early detection of bladder cancer.
    Clin Transl Med. 2025;15:e70540.
    

    >> Share

    
    

    
    Cureus

28. MOHAMMED S, Aniah M, Saougki C, Ibrahim AE, et al
    Understanding Treatment Completion and Tolerability of Intravesical Bacillus Calmette-Guerin (BCG) for Non-muscle Invasive Bladder Cancer in a Single UK Health Board.
    Cureus. 2025;17:e98655.
    

    >> Share

    
    

    
    Diagnostics (Basel)

29. YANG X, Guo Y, Wang L, Miao Z, et al
    Overexpression of CDC20 Confer a Poorer Prognosis in Bladder Cancer Identified by Gene Co-Expression Network Analysis.
    Diagnostics (Basel). 2025;15:3016.
    

    >> Share

    
    
30. IKUMA S, Akatsuka J, Kaneko G, Takeda H, et al
    A Composite Risk Score Based on VI-RADS, Tumor Contact Length, and CYFRA 21-1 for Prognostic Stratification in Bladder Cancer.
    Diagnostics (Basel). 2025;15:2968.
    

    >> Share

    
    

    
    Discov Oncol

31. QIN R, Li C, Liu C, Shen C, et al
    Combining machine learning and molecular docking to unravel the molecular network of bladder cancer induced by 2-naphthylamine.
    Discov Oncol. 2025 Dec 10. doi: 10.1007/s12672-025-04260.
    

    >> Share

    
    
32. XIAO L, Wang Y, Xiong Y, Zhuang Z, et al
    Integrated multi-omics analysis identifies DARS2, MRTO4, and MRPL37 as novel biomarkers and potential therapeutic targets for bladder cancer.
    Discov Oncol. 2025 Dec 9. doi: 10.1007/s12672-025-04246.
    

    >> Share

    
    

    
    Dose Response

33. ZHAO W, Xie Z, Zhu L, Li W, et al
    TSN Disrupts Fanconi Anemia Pathway Activation Through JAK/STAT1-Mediated Transcriptional Repression of FA Core Subunits in Bladder Cancer.
    Dose Response. 2025;23:15593258251406039.
    

    >> Share

    
    

    
    Ecotoxicol Environ Saf

34. ZHU J, Yi B, Ma J, Zhang S, et al
    Ozone aging amplifies the tumor-promoting effects associated with low-dose graphene oxide exposure in bladder tumors via the integrin alphaV signaling pathway.
    Ecotoxicol Environ Saf. 2025;307:119458.
    

    >> Share

    
    

    
    Eur J Med Res

35. WANG P, Li C, Xu Y, Altuwaijri S, et al
    CEACAM6 regulates glycolytic metabolism in bladder cancer cell by controlling ENO1 stability.
    Eur J Med Res. 2025;30:1233.
    

    >> Share

    
    

    
    Eur Urol

36. KHENE ZE, Bensalah K, Roupret M
    Artificial Intelligence for Risk Prediction in Non-muscle-invasive Bladder Cancer: From Complexity to Clinical Clarity.
    Eur Urol. 2025 Dec 3:S0302-2838(25)04831-6. doi: 10.1016/j.eururo.2025.
    

    >> Share

    
    

    
    Eur Urol Focus

37. MEEKS JJ
    Urothelial Cancer: What Is the Role of Expression-based Subtypes to Guide Neoadjuvant Therapy in Muscle-invasive Bladder Cancer?
    Eur Urol Focus. 2025 Dec 4:S2405-4569(25)00346-3. doi: 10.1016/j.euf.2025.
    

    >> Share

    
    
38. LAURIDSEN SV, Tonnesen H, Thind P, Rasmussen M, et al
    Impact of a Perioperative Smoking and Alcohol Cessation Intervention on Health-related Quality of Life in Patients Undergoing Radical Cystectomy: A Randomised Controlled Trial.
    Eur Urol Focus. 2025;11:940-950.
    

    >> Share

    
    

    
    Eur Urol Oncol

39. LEUNG DK, Wong CH, Ko IC, Siu BW, et al
    Global Trends in the Incidence, Mortality, and Risk-attributable Deaths for Prostate, Bladder, and Kidney Cancers: A Systematic Analysis from the Global Burden of Disease Study 2021.
    Eur Urol Oncol. 2025;8:1533-1543.
    

    >> Share

    
    

    
    Eur Urol Open Sci

40. LIU K, Liu AQ, Zhao H, Wong CH, et al
    Impact of H1 Antihistamines on Bacillus Calmette-Guerin-treated Non-muscle-invasive Bladder Cancer.
    Eur Urol Open Sci. 2025;83:23-29.
    

    >> Share

    
    

    
    Expert Rev Mol Diagn

41. TOMASSEN YL, Gibb EA, Lotan Y, de Jong JJ, et al
    Unlocking the potential of long non-coding RNAs in bladder cancer.
    Expert Rev Mol Diagn. 2025 Dec 13:1-4. doi: 10.1080/14737159.2025.2603407.
    

    >> Share

    
    

    
    FEBS Open Bio

42. LEYPOLD S, Riese J, Seillier L, Kuhnel M, et al
    Tumor-stromal crosstalk and macrophage enrichment are associated with chemotherapy response in bladder cancer.
    FEBS Open Bio. 2025 Dec 12. doi: 10.1002/2211-5463.70179.
    

    >> Share

    
    

    
    Fr J Urol

43. MOLLOT-GRANGER S, Chabrot P, Xardel V, Charbonnel C, et al
    Interim analysis of the IRMAA study: concordance between MRI and histopathological analysis of bladder cancer.
    Fr J Urol. 2025 Dec 10:103065. doi: 10.1016/j.fjurol.2025.103065.
    

    >> Share

    
    
44. CHAPUIS M, Wandoren W, Haudebert C, Richard C, et al
    Ureteroenteric repair for strictures after radical cystectomy and urinary diversion: Comparison of the open and robotic approaches.
    Fr J Urol. 2025;35.
    

    >> Share

    
    
45. CHABENES M, Fiard G, Blanc N, Delay M, et al
    Functional and urodynamics outcomes after robot-assisted cystoprostatectomy with intracorporeal neobladder: Impact of the learning curve.
    Fr J Urol. 2025;35:102997.
    

    >> Share

    
    

    
    Front Genet

46. GUO X, Li G
    SHMT2 modulates the transcriptome and metabolism profiles to promote the tumor phenotypes of bladder cancer HT-1376 cells.
    Front Genet. 2025;16:1694089.
    

    >> Share

    
    

    
    Front Immunol

47. POLAK L, Hojeij R, Cesson V, Haefliger JA, et al
    Characterization of Ty21a immunostimulatory effects in the mouse bladder.
    Front Immunol. 2025;16:1629462.
    

    >> Share

    
    
48. LANGFELDER P, Lin ET, Tsai YT, Cha TL, et al
    Gene signature for response prediction to immunotherapy and prognostic markers in metastatic urothelial carcinoma.
    Front Immunol. 2025;16:1607222.
    

    >> Share

    
    
49. DONG X, Fu X, Zhang H, Ma Y, et al
    Durable complete response to PD-1 inhibitor in vesical calculus-associated squamous cell carcinoma: a case report.
    Front Immunol. 2025;16:1688443.
    

    >> Share

    
    

    
    Front Oncol

50. RUOJING W, Yuan S, Feiya S, Lijuan Y, et al
    Deep learning-based survival analysis of bladder cancer patients in the Putuo District, Shanghai, China.
    Front Oncol. 2025;15:1619309.
    

    >> Share

    
    
51. HU X, Xie T, Xiao X, Mei Y, et al
    LncRNA ELDR promotes bladder cancer malignant progression by regulating the miR-1343-3p/TRIM44 axis.
    Front Oncol. 2025;15:1685792.
    

    >> Share

    
    

    
    Healthcare (Basel)

52. HOU Y, Zhang Q, Ma B
    Kidney, Prostate, and Bladder Cancer Burden Attributable to Tobacco Smoke Exposure in BRICS Countries from 1990 to 2021: A Systematic Analysis Based on the Global Burden of Disease Study.
    Healthcare (Basel). 2025;13:3082.
    

    >> Share

    
    

    
    Histopathology

53. LOPEZ-BELTRAN A, Blanca A, Downes MR, Cimadamore A, et al
    Molecular pathology of bladder cancer.
    Histopathology. 2026;88:65-85.
    

    >> Share

    
    
54. DOWNES MR, van der Kwast TH, Lopez-Beltran A, Cheng L, et al
    Grading of bladder cancer: updates, controversies and practical solutions.
    Histopathology. 2026;88:86-107.
    

    >> Share

    
    
55. WOJCIK EM
    The Paris system for reporting urinary cytology: what worked and what still needs to be improved.
    Histopathology. 2026;88:131-136.
    

    >> Share

    
    
56. AKBULUT D, Al-Ahmadie H
    Neuroendocrine tumours of the urinary bladder: recent advances.
    Histopathology. 2026;88:108-121.
    

    >> Share

    
    

    
    Indian J Pathol Microbiol

57. VENKATAKRISHNAN S, Jinkala SR, Sreerag KS, Kayal S, et al
    Basal subtype of invasive urothelial carcinoma of the bladder has aggressive behavior and poor prognosis: An immunohistochemistry-based study.
    Indian J Pathol Microbiol. 2025;68:736-743.
    

    >> Share

    
    

    
    Int J Mol Sci

58. BRAUN JP, Palattao KAD Jr, Torbenson E, Hsia B, et al
    Genomic Characteristics of Bladder Cancer: An AACR Project GENIE Study.
    Int J Mol Sci. 2025;26:11653.
    

    >> Share

    
    

    
    Int J Nanomedicine

59. CHEN Y, Zheng B, Liu Z, Wang H, et al
    Dual-Spherical Multifunctional Nanomotors for Intravesical Bladder Cancer Therapy.
    Int J Nanomedicine. 2025;20:14613-14628.
    

    >> Share

    
    

    
    Int J Surg

60. YU N, Li J, Cao D, Chen X, et al
    CT-based radiomics signature of visceral adipose tissue for prediction of early recurrence in patients with NMIBC: a multicentre cohort study.
    Int J Surg. 2025;111:9457-9470.
    

    >> Share

    
    

    
    Int J Urol

61. MIYAKE M, Nishimura N, Taoka R, Miki J, et al
    Real-World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical Bacillus Calmette-Guerin (BCG) Therapy in BCG-Naive or -Unresponsive Non-Muscle-Invasive Bladder Cancer.
    Int J Urol. 2025 Dec 12. doi: 10.1111/iju.70314.
    

    >> Share

    
    
62. SHIOZAKI M, Minagawa T, Yokoyama H, Hirotsu Y, et al
    Prediction of Postoperative Intravesical Recurrence Using Urine DNA Monitoring in Nonmuscular-Invasive Urothelial Bladder Cancer.
    Int J Urol. 2025 Dec 9. doi: 10.1111/iju.70293.
    

    >> Share

    
    
63. HORI T, Nohara T, Kawahara T, Nakagawa R, et al
    Association Between Preoperative 5-Aminolevulinic Acid Administration Timing and Perioperative Hypotension.
    Int J Urol. 2025;32:1827-1833.
    

    >> Share

    
    
64. NOMURA N, Sekino Y, Hayashi T, Kobayashi G, et al
    TUBB3 Is Associated With a Poor Prognosis and Basal Subtypes in Upper and Lower Tract Urothelial Carcinoma.
    Int J Urol. 2025;32:1893-1901.
    

    >> Share

    
    
65. KOBATAKE K, Goto K, Hatayama T, Naito M, et al
    Efficacy of Open-Ended Urinary Catheters in Preventing Catheter-Related Bladder Discomfort: A Randomized Controlled Trial.
    Int J Urol. 2025;32:1819-1826.
    

    >> Share

    
    

    
    Int Urol Nephrol

66. ZHANG W, Wei Q, Han X, Zheng X, et al
    Global, regional, and national burdens of bladder cancer in individuals aged 60 years and older from 1990 to 2021: a cross-sectional study.
    Int Urol Nephrol. 2025 Dec 9. doi: 10.1007/s11255-025-04941.
    

    >> Share

    
    
67. SONG Z, Wang Y, Yu C, Sha K, et al
    ZSTK474 suppresses bladder cancer cell migration and invasion via PI3K/Akt/Girdin pathway: an in vitro study.
    Int Urol Nephrol. 2025 Dec 5. doi: 10.1007/s11255-025-04940.
    

    >> Share

    
    

    
    J Cachexia Sarcopenia Muscle

68. ENGELMANN SU, Kasparbauer F, Pickl C, Del Giudice F, et al
    Interplay of IL-6, GDF-15 and Sarcopenia in Patients With Bladder Cancer Undergoing Radical Cystectomy and Its Implications on Survival.
    J Cachexia Sarcopenia Muscle. 2025;16:e70146.
    

    >> Share

    
    

    
    J Ethnopharmacol

69. LIU YX, Song YS, Liu CK, Liu J, et al
    Paris polyphylla Smith var. yunnanensis-derived saponins potentiate the antitumor activity of GPX4 inhibitors.
    J Ethnopharmacol. 2026;357:120890.
    

    >> Share

    
    

    
    J Exp Clin Cancer Res

70. PANNHAUSEN J, Chughtai AA, Yuce CL, Melzer MK, et al
    Targeting ATR offers multifaceted treatment strategies involving RAD51-mediated compensatory DNA repair in bladder cancer.
    J Exp Clin Cancer Res. 2025 Dec 12. doi: 10.1186/s13046-025-03603.
    

    >> Share

    
    

    
    J Natl Cancer Inst

71. LIU B, Floud S, Yang L, Yang TO, et al
    Prospective associations of diabetes with 15 cancers in 2.2 million UK and Chinese adults.
    J Natl Cancer Inst. 2025;117:2477-2487.
    

    >> Share

    
    

    
    J Transl Med

72. TANAKA S, Wilkens LR, Marchand LL, Yang G, et al
    Developing a prediction model in a large case-control study for the early detection of bladder cancer.
    J Transl Med. 2025 Dec 5. doi: 10.1186/s12967-025-07511.
    

    >> Share

    
    

    
    J Urol

73. CHANG SS, Chamie K, Kramolowsky E, Gonzalgo ML, et al
    Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guerin in Bacillus Calmette-Guerin-Unresponsive Papillary-Only Nonmuscle-Invasive Bladder
    J Urol. 2026;215:44-56.
    

    >> Share

    
    

    
    JAMA Ophthalmol

74. PAN WW, Waters I, Yousif J, Reichert ZR, et al
    Acute and Substantial Vision Loss After Pembrolizumab Immunotherapy for Bladder Cancer.
    JAMA Ophthalmol. 2025 Dec 11. doi: 10.1001/jamaophthalmol.2025.5068.
    

    >> Share

    
    

    
    JCO Oncol Pract

75. ABIDOYE O, Jain P, Singh P
    Lines of Therapy for Locally Advanced/Metastatic Urothelial Carcinoma: The New Paradigm.
    JCO Oncol Pract. 2025;21:1765-1773.
    

    >> Share

    
    

    
    Medicine (Baltimore)

76. BAI J, Wang L
    Blood urea nitrogen and bladder cancer: A Mendelian randomization study.
    Medicine (Baltimore). 2025;104:e46046.
    

    >> Share

    
    
77. CHAI J, Feng R, Wang A, Zhang T, et al
    Ectopic adrenal tissue around the prostate: A rare case.
    Medicine (Baltimore). 2025;104:e46287.
    

    >> Share

    
    

    
    Mol Oncol

78. SCHLOSSER RM, Krumbach F, Corrales E, Andrieux G, et al
    Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal-like and malignant urothelial cells.
    Mol Oncol. 2025;19:3784-3805.
    

    >> Share

    
    

    
    Molecules

79. SILVA A, Felix AM, Goncalves CS, Longatto-Filho A, et al
    Functional and Mechanistic Insights of 3-Hydroxybutyrate (3-OBA) in Bladder Cancer.
    Molecules. 2025;30:4624.
    

    >> Share

    
    

    
    NPJ Digit Med

80. LIU J, Sun S, Guo Y, Gu Z, et al
    Integrative molecular-radiopathomic characterization of AIRE-driven immune subtypes in bladder cancer.
    NPJ Digit Med. 2025 Dec 14. doi: 10.1038/s41746-025-02091.
    

    >> Share

    
    

    
    Oncoimmunology

81. RUIZ-LORENTE I, Gimeno L, Lopez-Abad A, Cubillana PL, et al
    HLA class-I genotyping to personalize Bacille Calmette-Guerin immunotherapy in bladder cancer.
    Oncoimmunology. 2025;14:2598920.
    

    >> Share

    
    

    
    Oncol Rev

82. SINGH V, Singh MK, Kumar A, Shrivastava A, et al
    DNA methylation as prognostic factors in non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Oncol Rev. 2025;19:1679974.
    

    >> Share

    
    

    
    Oncologist

83. SUN M, Ju M, Zhang H, Huang N, et al
    Clinical characteristics of the ALK fusion-positive bladder PMP and efficacy of lorlatinib: a two-case report and literature review.
    Oncologist. 2025;30:oyaf389.
    

    >> Share

    
    

    
    Phys Med

84. SAPIGNOLI S, Bettinelli A, Caricato P, Amico AG, et al
    Bladder surface-based analysis proves the advantages of online adaptive radiotherapy over plan of the day.
    Phys Med. 2025;140:105677.
    

    >> Share

    
    

    
    Planta Med

85. YANG CW, Chen CY, Yen CH, Shu CW, et al
    Threo-2,3-bis-(4-hydroxy-3-methoxyphenyl)-3-methoxypropanol (THMP) Inhibits Bladder Cancer Cell Proliferation via Oxidative Stress-dependent Apoptosis and DNA Damage.
    Planta Med. 2025 Dec 8. doi: 10.1055/a-2752-9897.
    

    >> Share

    
    

    
    PLoS One

86. VUORISTO L, Poyhonen A, Vuorlaakso SM, Kotsar A, et al
    Hyperglycemia and bladder cancer prognosis in a Finnish population-based cohort.
    PLoS One. 2025;20:e0338215.
    

    >> Share

    
    
87. FREY LJ, Banasiewicz KE, Ruckes C, Wagner I, et al
    Complications and oncologic outcome in bladder cancer patients receiving radical cystectomy after intravesical instillation treatment.
    PLoS One. 2025;20:e0337644.
    

    >> Share

    
    

    
    Radiother Oncol

88. SARGOS P, Pignot G, Bellera C, Pommier P, et al
    Adjuvant radiotherapy in patients with pathological high-risk bladder cancer: Acute toxicity results from a randomized multicentre phase II trial (Bladder-ART/GETUG-AFU30).
    Radiother Oncol. 2025;214:111326.
    

    >> Share

    
    

    
    Res Rep Urol

89. LU LL, Chen HZ, Chen JG
    Impact of Age, TNM Stage, and Hospitalization on Bladder Cancer Survival: Evidence from a Hospital-Based Cohort in Eastern China.
    Res Rep Urol. 2025;17:481-493.
    

    >> Share

    
    

    
    Res Vet Sci

90. HOGGARD NK, Elshafae SM, Daniels NA, Young JA, et al
    Comparative histologic survey and transcriptomic investigation into canine prostate carcinoma.
    Res Vet Sci. 2026;198:105981.
    

    >> Share

    
    

    
    Sci Rep

91. ZHANG W, Deng LL, Xia YY, Wei MY, et al
    Multi-omics profiling identifies ESM1 as a key mediator of immunoevasion through the SPP1 pathway in bladder cancer.
    Sci Rep. 2025;15:43439.
    

    >> Share

    
    
92. MAO Q, Liu H, Liu S, Wang W, et al
    Uncovering the prognostic implications and immunological roles of transmembrane protein 208 in bladder cancer by multi omics analysis and experimental verification.
    Sci Rep. 2025;15:43503.
    

    >> Share

    
    

    
    Semin Nucl Med

93. SAFARIAN A, Muin D, Unterrainer L, Hormann A, et al
    The role of non-FDG agents in PET imaging of bladder cancer.
    Semin Nucl Med. 2025 Dec 8:S0001-2998(25)00165.
    

    >> Share

    
    

    
    Theranostics

94. XU Y, Du Q, Zhao Z, Fu S, et al
    Targeted Accumulation of Reactive Acrolein via Nanoparticle-embedded Reverse Temperature Hydrogel for Bladder Cancer Treatment.
    Theranostics. 2026;16:1528-1544.
    

    >> Share

    
    

    
    Transl Androl Urol

95. ABOU CHAKRA M, Duquesne I, Mima M, Moussa M, et al
    Global insights into the management of BCG-unresponsive non-muscle invasive bladder cancer: a narrative review of provider surveys.
    Transl Androl Urol. 2025;14:3782-3793.
    

    >> Share

    
    
96. HAN K, Wei C, Li Y, Luo Y, et al
    Integration of genetic, proteomic, and transcriptomic data identifies therapeutic targets and prognostic biomarkers in bladder cancer.
    Transl Androl Urol. 2025;14:3472-3492.
    

    >> Share

    
    

    
    Transl Oncol

97. SHI Y, Sun J, Yu K, Lu D, et al
    piR-43452 suppresses bladder cancer progression and enhances gemcitabine sensitivity via GTSF1/PIWIL4-mediated LRP1 mRNA destabilization.
    Transl Oncol. 2025;63:102626.
    

    >> Share

    
    

    
    Urol Oncol

98. MYERS AA, Duan Z, Igel DA, Steinmetz AR, et al
    Disparities and temporal trends in referral for bladder cancer diagnosis: A worsening epidemic.
    Urol Oncol. 2025 Dec 10:S1078-1439(25)00477.
    

    >> Share

    
    
99. GOKHALE P, Akosah A, Villa Zapata L
    Immune-related adverse events associated with immune checkpoint inhibitor therapy in bladder cancer patients: A systematic review and meta-analysis.
    Urol Oncol. 2025 Dec 10:S1078-1439(25)00470.
    

    >> Share

    
    
100. CHANG JC, Perez-Londono A, Kaul S, Almohtasib J, et al
     Dynamic prognostication of non-muscle invasive bladder cancer using conditional recurrence- and progression-free survival: A SEER-Medicare analysis.
     Urol Oncol. 2025 Dec 9:S1078-1439(25)00452-1. doi: 10.1016/j.urolonc.2025.
     

     >> Share

     
     
101. KAYAR K, Kayar R, Sonmez D, Hakan MT, et al
     Evaluation of kynurenine and tryptophan metabolism in bladder cancer: Diagnostic and prognostic implications of IDO1 polymorphism.
     Urol Oncol. 2025 Dec 8:S1078-1439(25)00475-2. doi: 10.1016/j.urolonc.2025.
     

     >> Share

     
     
102. SAVAGE SJ, Ercole CE, Hemstreet G, Leone A, et al
     Diagnostic performance of Cxbladder Triage Plus for the identification and stratification of patients at risk for urothelial carcinoma: The multicenter, prospective, observational DRIVE study.
     Urol Oncol. 2026;44:65.
     

     >> Share

     
     
103. ZENG J, Tachibana I, Sadowski J, Yeap Y, et al
     Comparison of 4 local anesthetic techniques for open radical cystectomy: A prospective, randomized controlled trial.
     Urol Oncol. 2026;44:64.
     

     >> Share

     
     
104. ARTILES MEDINA A, Minguez Ojeda C, Subiela JD, Lopez Curtis D, et al
     A systematic review and meta-analysis evaluating the incidence, microbiological profile and risk factors associated with urinary tract infection after radical cystectomy.
     Urol Oncol. 2025 Oct 28:S1078-1439(25)00399.
     

     >> Share

     
     
105. JINDAL T, Jiang CY, Alhalabi O, Davidsohn M, et al
     Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study.
     Urol Oncol. 2026;44:65.
     

     >> Share

     
     
106. KEARNEY M, Macmillan T, Poritz J, Schreiber-Gosche S, et al
     Measuring what matters to patients: Systematic literature review of patient-reported outcomes assessment and reporting in locally advanced or metastatic urothelial cancer real-world and clinical studies.
     Urol Oncol. 2026;44:63.
     

     >> Share

     
     
107. LAMA DJ, Jaime-Casas S, Imam A, Okunowo O, et al
     Renal ultrasound as a surveillance method for ureteroenteric anastomotic stricture following radical cystectomy and urinary diversion.
     Urol Oncol. 2026;44:64.
     

     >> Share

     
     

     
     Urology

108. CHOI IW, Ebert KM, Li Q, Finup JL, et al
     A Rare Case of Ewing Sarcoma Presenting in the Adult Bladder-Treatments and Need for More Discussion.
     Urology. 2025;206:90-93.
     

     >> Share

     
     

     
     Value Health

109. CAO X, Brouwer E, Chen Y, Ramsey S, et al
     Influence of initial imaging modality on peri-diagnostic outcomes among pancreatic, liver, ovarian, and bladder cancers without routine screening programs: A SEER-Medicare Study.
     Value Health. 2025 Dec 6:S1098-3015(25)06149-2. doi: 10.1016/j.jval.2025.
     

     >> Share

     
     

     
     Vet Immunol Immunopathol

110. YOKOTA S, Fujii W, Motegi T, Komori M, et al
     Sorafenib inhibits myeloid-derived suppressor cell infiltration in canine transitional cell carcinoma.
     Vet Immunol Immunopathol. 2025;290:111019.
     

     >> Share

     
     

Free Medical Abstracts
Privacy Policy
Sponsors
Share